20 research outputs found
Incessant Tachycardia Using a Concealed Atrionodal Bypass Tract
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72624/1/j.1540-8167.1998.tb00899.x.pd
A Prospective Evaluation of Two Defibrillation Safety Margin Techniques in Patients with Low Defibrillation Energy Requirements
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75077/1/j.1540-8167.1998.tb00865.x.pd
Differential Effect of Adenosine on Anterograde and Retrograde Fast Pathway Conduction in Patients with Atrioventricular Nodal Reentrant Tachycardia
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72925/1/j.1540-8167.1998.tb00121.x.pd
Effect of Ventricular Shock Strength on Cardiac Hemodynamics
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75115/1/j.1540-8167.1998.tb00118.x.pd
Long-Term Evaluation of the Ventricular Defibrillation Energy Requirement
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/74692/1/j.1540-8167.1998.tb00132.x.pd
Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs
Federal and state agencies granted temporary regulatory waivers to prevent disruptions in access to medication for opioid use disorder (MOUD) during the COVID-19 pandemic, including expanding access to telehealth for MOUD. Little is known about changes in MOUD receipt and initiation among Medicaid enrollees during the pandemic.To examine changes in receipt of any MOUD, initiation of MOUD (in-person vs telehealth), and the proportion of days covered (PDC) with MOUD after initiation from before to after declaration of the COVID-19 public health emergency (PHE).This serial cross-sectional study included Medicaid enrollees aged 18 to 64 years in 10 states from May 2019 through December 2020. Analyses were conducted from January through March 2022.Ten months before the COVID-19 PHE (May 2019 through February 2020) vs 10 months after the PHE was declared (March through December 2020).Primary outcomes included receipt of any MOUD and outpatient initiation of MOUD via prescriptions and office- or facility-based administrations. Secondary outcomes included in-person vs telehealth MOUD initiation and PDC with MOUD after initiation.Among a total of 8 167 497 Medicaid enrollees before the PHE and 8 181 144 after the PHE, 58.6% were female in both periods and most enrollees were aged 21 to 34 years (40.1% before the PHE; 40.7% after the PHE). Monthly rates of MOUD initiation, representing 7% to 10% of all MOUD receipt, decreased immediately after the PHE primarily due to reductions in in-person initiations (from 231.3 per 100 000 enrollees in March 2020 to 171.8 per 100 000 enrollees in April 2020) that were partially offset by increases in telehealth initiations (from 5.6 per 100 000 enrollees in March 2020 to 21.1 per 100 000 enrollees in April 2020). Mean monthly PDC with MOUD in the 90 days after initiation decreased after the PHE (from 64.5% in March 2020 to 59.5% in September 2020). In adjusted analyses, there was no immediate change (odds ratio [OR], 1.01; 95% CI, 1.00-1.01) or change in the trend (OR, 1.00; 95% CI, 1.00-1.01) in the likelihood of receipt of any MOUD after the PHE compared with before the PHE. There was an immediate decrease in the likelihood of outpatient MOUD initiation (OR, 0.90; 95% CI, 0.85-0.96) and no change in the trend in the likelihood of outpatient MOUD initiation (OR, 0.99; 95% CI, 0.98-1.00) after the PHE compared with before the PHE.In this cross-sectional study of Medicaid enrollees, the likelihood of receipt of any MOUD was stable from May 2019 through December 2020 despite concerns about potential COVID-19 pandemic–related disruptions in care. However, immediately after the PHE was declared, there was a reduction in overall MOUD initiations, including a reduction in in-person MOUD initiations that was only partially offset by increased use of telehealth
Inferior vena cava-right atrial junction stenosis requiring a multidisciplinary approach to resection and reconstruction.
Recommended from our members
The Human Health Benefits of Improving Forest Health in California: Investigating the Links Between Forest Management, Wildfire Smoke, and the Health Sector
Our report examines the connections between forest management, wildfire smoke, and human health through interviews with health sector organizations in California and a review of the scientific literature. We highlight the knowledge gaps and the data, research, and collaborations needed to effectively fill them, as well as steps the State of California, the federal government, and others can take to ensure the improved health of all who live under frequently smoky skies. Broadly, we find:
1. Wildfire smoke impacts human health and health sector organizations’ workforces, operations, and ability to provide services, yet the costs are largely unquantified. Quantifying these costs would enable state and local health sector organizations to make more informed decisions regarding budgeting, resource allocation, and response.2. Many interviewed health sector organizations see value in future engagement with forest management to mitigate adverse outcomes and costs associated with wildfire smoke, but require avenues for collaboration and more information on the potential benefits of forest management to human health and the health sector.3. Comprehensive statewide and/or locally specific information on the adverse human health impacts of wildfire smoke are not readily available but could be generated from additional analysis of existing data resources. The data and methodologies to support the above understanding require thoughtful, forward-looking, collaborative, coordinated research design that is informed by use cases appropriate for California.4. A small but growing body of research suggests that management to improve forest health can be tailored to reduce total smoke impacts and benefit human health. Informed prioritization of management strategies that promote forest resilience and human health across California’s many landscapes will benefit from filling data gaps relating the costs and efficacy of various treatments under different conditions